Literature DB >> 4041333

Haemodialysis does not affect the pharmacokinetics of nifedipine.

H Martre, R Sari, A M Taburet, C Jacobs, E Singlas.   

Abstract

To establish dosage recommendations in patients with end-stage renal disease undergoing chronic haemodialysis, nifedipine kinetics were studied between and during haemodialysis sessions. In eight patients, during the interdialytic period, peak plasma concentrations of nifedipine (29-332 ng/ml) were reached 0.5-1.0 h after administration of a single 10 mg oral dose. Elimination half-life and oral plasma clearance were respectively 2.6 +/- 0.5 h and 1 176 +/- 412 ml/min. Nifedipine plasma protein binding was decreased in uraemic patients (88.8 +/- 0.3% vs 94.4 +/- 0.1%) but not affected by haemodialysis. Removal by haemodialysis was low: the dialyser extraction ratio and the dialysis clearance were respectively 2.3 +/- 0.8% and 2.8 +/- 0.9 ml/min.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4041333      PMCID: PMC1400667          DOI: 10.1111/j.1365-2125.1985.tb05049.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors.

Authors:  I Sjöholm; A Kober; I Odar-Cederlöf; O Borgåa
Journal:  Biochem Pharmacol       Date:  1976-05-15       Impact factor: 5.858

2.  The effect of dialysis on the protein binding of drugs in the plasma of patients with acute renal failure.

Authors:  F Andreasen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1974-04

3.  Ischaemic myocardial damage in chronic renal failure.

Authors:  K Lewin; L Trautman
Journal:  Br Med J       Date:  1971-10-16

4.  Gas chromatographic determination of nifedipine and one of its metabolites using electron capture detection.

Authors:  P Jakobsen; O Lederballe Pedersen; E Mikkelsen
Journal:  J Chromatogr       Date:  1979-01-01

Review 5.  The binding of drugs to plasma proteins from patients with poor renal function.

Authors:  M M Reidenberg
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Alteration of plasma albumin in relation to decreased drug binding in uremia.

Authors:  S W Boobis
Journal:  Clin Pharmacol Ther       Date:  1977-08       Impact factor: 6.875

7.  [The binding of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (nifedipine) as well as other coronary active substances to serum albumins].

Authors:  H Rosenkranz; K Schlossmann; W Scholtan
Journal:  Arzneimittelforschung       Date:  1974-04

8.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

9.  Effects of nifedipine on resistance vessels, arteries and veins in man.

Authors:  B F Robinson; R J Dobbs; C R Kelsey
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

10.  Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.

Authors:  T S Foster; S R Hamann; V R Richards; P J Bryant; D A Graves; R G McAllister
Journal:  J Clin Pharmacol       Date:  1983-04       Impact factor: 3.126

View more
  7 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis.

Authors:  Nicolas K Kambia; Thierry Dine; Pascal Odou; Salmane Bah; Raymond Azar; Bernard Gressier; Thérèse Dupin-Spriet; Michel Luyckx; Claude Brunet
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Oct-Dec       Impact factor: 2.441

Review 3.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

Review 4.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.

Authors:  J H Ahmed; A C Grant; R S Rodger; G R Murray; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

7.  Pharmacokinetics of nisoldipine in renal dysfunction.

Authors:  J Boelaert; Y Valcke; H Dammekens; G De Vriese; G Ahr; M Schurgers; R Daneels; M G Bogaert
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.